Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Head of DPAG David Paterson joins Lord David Willets, Dame Ottoline Leyser and Priya Guha in discussing the future priorities for UK Research and Innovation (UKRI) - summaries are now published in The Foundation for Science and Technology Journal.

In November 2020, a meeting of the Foundation for Science and Technology (FTS) chaired by the Rt Hon Lord Willetts FRS, former Minister for Universities and Science, explored how the UK Research and Innovation (UKRI) should develop, particularly in light of the challenges posed by Brexit and the coronavirus pandemic. The meeting brought together the UKRI's Chief Executive Professor Dame Ottoline Leyser, Innovate UK Council member and Venture Partner at Merian Ventures Priya Guha, and DPAG's Head of Department and President of the Physiological Society Professor David Paterson.

Professor Paterson delivered a talk on "Assessing the real value of research", during which he noted that the UK needs to become better at bringing together the whole research landscape. This is particularly key in the context of the COVID-19 pandemic:

One of the challenges for UKRI is to set up a funding framework which can still focus on the reductive aspects of our science while not losing sight of the whole. COVID-19 is a multi-organ disease and this is classically where three different disciplines meet - physiology, neuroscience and immunology. To be able to set up funding structures in response mode to deal with this kind of challenge is very important.- Professor David Paterson

Professor Paterson also indicated two key issues that need addressing in the world of research funding for UK science: pressure on the Quality-related research (QR) funding support model, and whether the Research Excellence Framework (REF), which is the framework to help distribution within QR, is fit for purpose. He also notes the inherent difficulties in assessing academic success, as while they are not mutually exclusive, the answers may be different in mission science and discovery science. 

A summary of Professor Paterson's talk, together with talks from Dame Ottoline Leyster on "Creating a flexible, inter-connected and effective system" and Priya Guha on "Making the most of our innovative start-ups" can be read online in the latest issue of the FTS JournalView the full issue.

Videos of the presentations from the 2020 meeting can be accessed on the FTS Events website.

Similar stories

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Experimental Medicine and Industry Partnership

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between a core team of Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institute, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.